Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study

• Váldodahkkit: Giuseppe Migliorisi (Dahkki), Mirella Collura (Dahkki), Francesca Ficili (Dahkki), Tiziana Pensabene (Dahkki), Dafne Bongiorno (Dahkki), Antonina Collura (Dahkki), Francesca Di Bernardo (Dahkki), Stefania Stefani (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2022-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The use of modulator drugs that target the Cystic Fibrosis transmembrane conductance regulator (CFTR) is the final frontier in the treatment of Cystic Fibrosis (CF), a genetic multiorgan disease. F508del is the most common mutation causing defective formation and function of CFTR. Elexacaftor-tezaca...